Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Journal of Neurology, Neurosurgery, and Psychiatry|September 5, 2018
How common is truly benign MS in a UK population?Emma Clare Tallantyre, Paula C Major, Michael J Atherton, et al.Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.Neurology|June 15, 2023
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third EditionAndrew J Solomon, Ruth Ann Marrie, Shanthi Viswanathan, et al.Neurology(R) Neuroimmunology & Neuroinflammation|June 6, 2020
Detecting and predicting neutralization of alemtuzumab responses in MSGauri Saxena, James M Moore, Meleri Jones, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2026
Genetic subtypes associated with multiple sclerosis severity and response to treatmentKarim L Kreft, Nienke J Mekkes, Emeka Uzochukwu, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 14, 2011
The motor phenotype of Parkinson's disease in relation to age at onsetMirdhu M Wickremaratchi, M Duleeka W Knipe, B S Dwarakanath Sastry, et al.Journal of Neuroinflammation|November 23, 2020
CCN3 is dynamically regulated by treatment and disease state in multiple sclerosisMichelle Naughton, Jill Moffat, George Eleftheriadis, et al.Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.Scientific Reports|October 18, 2016
Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodiesMathew Clement, James A Pearson, Stephanie Gras, et al.Multiple Sclerosis and Related Disorders|June 14, 2022
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosisEmma C Tallantyre, Martin J Scurr, Nicola Vickaryous, et al.Pageof 7